Many patients are being offered IR and that's a good thing, but wouldn't Ibrutinib alone be a better choice for nearly everyone. For the whole story, please take a look at my review of latest data and context of this important research.
cllsociety.org/2019/08/ibru... Brian Koffman CLLSociety,org
Thank you Brian for this review! As a newly (10 months) diagnosed CLL’er (who is hoping for years of w&w) I really appreciate this insight into ever evolving treatment. Thank you! GP
Thank you for sharing.
It’s my understanding the new roll for Ibrutinib is an 18 month cycle so there’s no issue with immunity. This study looks at a 5 year outlook. Is there a graph showing people that have taken Ibrutinib for 18 months with a 5 year graph showing the same results ? Or is this a study that still needs to be done. I don’t have any articles I can post on what and where I’ve seen this. But I’ve seen it on this forum.
Thanks John
One question I would have is whether resistance to ibrutinib develops more slowly in those who also had rituximab. It’s possible that’s the case since any pre existing mutated clones might be killed off by rituximab in those first few months.
What do you think of venetoclax plus rituximab or obinituzimab that seems to have more people believing the combo makes a difference.
And of course the acalabrutinib plus venetoclax plus obinituzimab combo trial looks very interesting too
No evidence of better responses adding R to I. Other combos are more promising.
Agreed. Dr. Byrd spells it out clearly here: ncbi.nlm.nih.gov/pmc/articl...
"In no setting outside of clinical trials should rituximab be administered together with ibrutinib as part of a continuous treatment regimen for CLL."
Stopping ibrutinib before a dental visit.
Update on ibrutinib treatment 
Ibrutinib and Cataract surgery
When (if ever) will Ibrutinib become available in the UK?
